1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer by Stahel, R et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2011
1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell
lung cancer
Stahel, R; Thatcher, N; Früh, M; Le Péchoux, C; Postmus, P E; Sorensen, J B; Felip, E
Abstract: The 1st ESMO Consensus Conference on lung cancer was held in Lugano, Switzerland on
21st and 22nd May 2010 with the participation of a multidisciplinary panel of leading professionals in
pathology and molecular diagnostics and medical, surgical and radiation oncology. Before the conference,
the expert panel prepared clinically relevant questions concerning five areas as follows: early and locally
advanced non-small-cell lung cancer (NSCLC), first-line metastatic NSCLC, second-/third-line NSCLC,
NSCLC pathology and molecular testing, and small-cell lung cancer (SCLC) to be addressed through
discussion at the Consensus Conference. All relevant scientific literature for each question was reviewed
in advance. During the Consensus Conference, the panel developed recommendations for each specific
question. The consensus agreement in SCLC is reported in this article. The recommendations detailed
here are based on an expert consensus after careful review of published data. All participants have
approved this final update.
DOI: https://doi.org/10.1093/annonc/mdr313
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-53283
Journal Article
Published Version
Originally published at:
Stahel, R; Thatcher, N; Früh, M; Le Péchoux, C; Postmus, P E; Sorensen, J B; Felip, E (2011). 1st
ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. Annals of Oncology,
22(9):1973-1980.
DOI: https://doi.org/10.1093/annonc/mdr313
Annals of Oncology 22: 1973–1980, 2011
doi:10.1093/annonc/mdr313
Published online 4 July 2011
special article
1st ESMO Consensus Conference in lung cancer;
Lugano 2010: Small-cell lung cancer
R. Stahel1,*, N. Thatcher2, M. Fru¨h3, C. Le Pe´choux4, P. E. Postmus5, J. B. Sorensen6, E. Felip7
& Panel members
1Department of Oncology, University Hospital Zurich, Zurich, Switzerland; 2Department of Medical Oncology, Christie Hospital, Manchester, UK; 3Department of
Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland; 4Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France;
5Department of Pulmonology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands; 6Department of Oncology, Finsen Centre/National University Hospital,
Copenhagen, Denmark; 7Department of Medical Oncology, Vall d’Hebron University Hospital, Barcelona, Spain
Received 8 April 2011; revised 11 May 2011; accepted 27 May 2011
The 1st ESMO Consensus Conference on lung cancer was held in Lugano, Switzerland on 21st and 22nd May 2010 with
the participation of a multidisciplinary panel of leading professionals in pathology and molecular diagnostics and medical,
surgical and radiation oncology. Before the conference, the expert panel prepared clinically relevant questions
concerning five areas as follows: early and locally advanced non-small-cell lung cancer (NSCLC), first-line metastatic
NSCLC, second-/third-line NSCLC, NSCLC pathology and molecular testing, and small-cell lung cancer (SCLC) to be
addressed through discussion at the Consensus Conference. All relevant scientific literature for each question was
reviewed in advance. During the Consensus Conference, the panel developed recommendations for each specific
question. The consensus agreement in SCLC is reported in this article. The recommendations detailed here are based on
an expert consensus after careful review of published data. All participants have approved this final update.
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Lugano 2010: Background to the ESMO
Consensus Conference
In 2009, European Society for Medical Oncology (ESMO)
decided to update the ESMO clinical recommendations in lung
cancer through a consensus process addressing five specific
areas:
1 -Early and locally advanced non-small-cell lung cancer
(NSCLC)
2 -NSCLC pathology and molecular testing
3 -First-line metastatic NSCLC
4 -Second-/third-line NSCLC
5 -Small-cell lung cancer (SCLC)
Five working groups were appointed, each comprised six to
eight participants with multidisciplinary involvement and led
by a chair, and with the assistance of one expert in
methodological aspects. A total of 39 experts were involved in
this consensus process (see Panel members listed in the
Appendix).
The 1st ESMO Consensus Conference on Lung Cancer
was held in May 2010 in Lugano. Before the conference, each
group identified a number of clinically relevant questions
suitable for consensus discussion and provided the available
literature. At the Conference, in five parallel sessions, each
group discussed and reached agreement on the questions
previously chosen. Decisions were made using studies
published in peer review journals. If no relevant published
data were identified, expert opinions were considered. The
consideration of abstracts was at the discretion of the
groups. All relevant scientific literature, as identified by the
experts, was considered. A systematic literature search was
not carried out. The recommendations from each group
were then presented to all the experts and discussed, and
a general consensus was reached. The ‘Infectious Diseases
Society of American-United States Public Health Service
Grading System’ was used (shown in Tables 1 and 2) for
level of evidence and strength of recommendation for each
question raised [1].
The consensus in SCLC is detailed here. SCLC remains an
important focus for treatment and research. The SCLC ESMO
Guidelines 2010 [2] were endorsed and should be read in
conjunction with these additional comments on specific
patient situations. Table 3 provides a summary of panel
recommendations. The final recommendations listed here have
been approved by all participants.
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STAGING ISSUES
1. What is limited stage?
Limited stage should be based on the TNM
(tumour–node–metastasis) 7 classification i.e. T1-4 N0-3 M0
[3]. In the new IASLC (International Association for the Study
of Lung Cancer) staging system, the largest difference in patient
outcomes was observed in patients with N1 versus N2 disease
(19 versus 14 months median survival, hazard ratio = 1.40,
P = 0.0001) [4]. Furthermore, tumour size was of particular
prognostic relevance in patients with N0/N1.
Recommendation 1: The new TNM 7 staging system for
NSCLC is to be adopted for SCLC.
Strength of recommendation: A
Level of evidence: I
2. Use of FDG–PET
Several studies have suggested that the old distinction between
limited and extensive stage can be improved with positron
Table 1. Level of evidence [1]
I Evidence from at least one large
randomised control trial of good
methodological quality (low potential
for bias) or meta-analyses of well-
conducted randomised trials without
heterogeneity
II Small randomised trials or large
randomised trials with a suspicion of
bias (lower methodological quality) or
meta-analyses of such trials or of trials
demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–
control studies
V Studies without control group, case
reports, experts opinions
Table 2. Strength of recommendation [1]
A Strong evidence for efficacy with
a substantial clinical benefit, strongly
recommended
B Strong or moderate evidence for efficacy
but with a limited clinical benefit,
generally recommended
C Insufficient evidence for efficacy or
benefit does not outweigh the risk or
the disadvantages (adverse events,
costs,. ), optional
D Moderate evidence against efficacy or for
adverse outcome, generally not
recommended
E Strong evidence against efficacy or for
adverse outcome, never recommended
Table 3. Summary of recommendations
Recommendations
Staging issues
Recommendation 1 The new TNM 7 staging system
for NSCLC is to be adopted for
SCLC
Recommendation 2 The use of PET is not based on
randomised trials and treatment
decisions should not be based on
PET findings alone. PET findings
which could modify treatment
decisions should be pathologically
confirmed
Recommendation 3 For a solitary extrathoracic metastasis
based on initial staging
examinations, pathologic proof is
often not feasible and may delay
treatment. Depending on the
clinical situation, early response
evaluation to initial chemotherapy
can be more appropriate in
deciding whether a solitary
metastasis is likely to be metastatic
or not. If bone is the sole metastatic
site, magnetic resonance imaging
may be preferred to more invasive
procedures
Treatment issues
First-line treatment
Recommendation 4 In patients with clinical T1-2 N0-1
stage that are potential surgical
patients, mediastinal node
exploration should be carried out.
Surgery may be indicated in
patients with no mediastinal
involvement, and resection should
be followed by chemotherapy.
Postoperative radiotherapy should
be considered for pathologic N1
and unforeseen N2 disease
Recommendation 5 First-line chemotherapy should be
offered to patients with metastatic
SCLC and PS 0–2. It may be
considered in selected cases in PS
3–4
Recommendation 6 Limited-stage patients with good PS
should be considered for
concomitant chemoradiotherapy,
taking into account the feasibility
of radiation treatment plan and
good planning target volume
coverage while maintaining
normal tissue dose constraints
Recommendation 7 Thoracic radiotherapy given either
concomitantly or sequentially is
currently not recommended in
patients with distant metastases
that have responded to
chemotherapy
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emission tomography (PET) and that it has a potential role
in adapting target volume for radiotherapy [5–8]. However,
histological confirmation of discordant PET findings is not
routinely carried out and the current studies have severe
limitations as regards pathologic correlation.
Recommendation 2: The use of PET is not based on
randomised trials and treatment decisions should not be based
on PET findings alone. PET findings, which could modify
treatment decisions, should be pathologically confirmed.
Strength of recommendation: C
Level of evidence: III
3. Single M1b
Recommendation 3.1: For a solitary extrathoracic metastasis
based on initial staging examinations, pathologic proof is often
not feasible and may delay treatment. Depending on the clinical
situation, early response evaluation to initial chemotherapy can
be more appropriate in deciding whether a solitary metastasis is
likely to be metastatic or not.
Strength of recommendation: C
Level of evidence: V
Recommendation 3.2: If bone is the sole metastatic site,
magnetic resonance imaging may be preferred to more invasive
procedures.
Strength of recommendation: B
Level of evidence: V
TREATMENT ISSUES: FIRST-LINE
TREATMENT
The figure shows a treatment algorithm using the new TNM 7
staging classification.
4. Should surgery be considered for any specific
subgroup?
Several retrospective reports on surgically treated early SCLC
patients indicated relatively favourable outcomes of this
approach if there was no mediastinal lymph node involvement
[9–11]. Randomised clinical trials addressing the role of surgery
and adjuvant chemotherapy versus combined
chemoradiotherapy in node-negative SCLC are lacking. The
panel believes that these retrospective data are consistent
enough to consider surgical approach in selected and
adequately staged SCLC patients.
Recommendation 4: In patients with clinical T1-2 N0-1 stage
who are potential surgical patients, mediastinal node exploration
should be carried out. Surgery may be indicated in patients with
no mediastinal involvement; resection should be followed by
chemotherapy. Postoperative radiotherapy should be considered
for pathologic N1 and unforeseen N2 disease.
Strength of recommendation: C
Level of evidence: V
5. What is the treatment of choice for
chemotherapy-naive patients with M1 disease?
Platinum/etoposide chemotherapy is a standard as
outlined in the 2010 ESMO recommendations [2]. A recent
Table 3. (Continued)
Recommendations
Recommendation 8 In patients with brain involvement as
the only metastatic site responding
to chemotherapy, concomitant
chemotherapy with thoracic
radiotherapy is currently not
recommended
Recommendation 9 PCI is recommended for patients
with tumour response. Response
should be determined by
a restaging CT scan
Recommendation 10 PCI in patients who are 65 years or
older, requires to balance the
benefit and risk of possible
neurocognitive impairment to be
considered
Follow-up issues
Recommendation 11 Subsequent follow-up should be at
2–3 months in non-progressing
patients at the end of initial
treatment and response
determination. The actual timing
depends on patient circumstances
and availability of further
treatment. Imaging with CT is
preferable
Treatment issues
Second-line treatment and
beyond
Recommendation 12 Sensitive disease: retreat with the
same regimen that induced their
initial response, usually
reinduction with platinum/
etoposide
Recommendation 13 Resistant disease: either oral or i.v.
topotecan is recommended for
selected patients having resistant
relapse, i.e. not amenable to
reinduction with first-line
treatment
Recommendation 14 Refractory disease and beyond
second-line treatment: selected
patients with good PS may benefit
from further treatment with
a chemotherapy agent not
previously used
Recommendation 15 Patients, not previously treated with
thoracic radiotherapy with
a symptomatic recurrence in the
mediastinum, such as superior
cava vein obstruction or
obstructed major airway, may
benefit from thoracic radiotherapy
Recommendation 16 Local brain re-irradiation, which
may include stereotactic
radiotherapy, may be considered
in selected patients
Annals of Oncology special article
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meta-analysis has suggested equivalence between irinotecan/
platinum and etoposide/platinum in extensive-stage patients
and a further study in Caucasian population has suggested
that irinotecan/cisplatin is not inferior to etoposide/cisplatin
[12, 13].
Recommendation 5: First-line chemotherapy should be
offered to patients with metastatic SCLC and performance
status (PS) of zero to two (scenario 1). It may be considered
in selected cases in PS of three to four (scenario 2).
Strength of recommendation: scenario 1: A; scenario 2: C
Level of evidence: scenario 1: I; scenario 2: V
6. Patient eligibility for early concurrent thoracic
radiotherapy on cycle 1 or 2
Patients with good PS are eligible for early concurrent
thoracic radiotherapy in cycle 1 or 2 [2, 14]. Computed
tomography (CT)-based three-dimensional conformal
radiotherapy is recommended. Use of FDG–PET for target
volume definition is being evaluated. There is no standard
dose that may vary between 45 Gy (twice daily) and 55–70 Gy
(once daily). Trials exploring the optimal dose and
fractionation are ongoing. There are no specific
recommendations for SCLC in terms of normal tissue
constraints. Based on NSCLC data, both V20 corresponding
to the percentage of normal lung parenchyma receiving 20 Gy
and the mean lung dose (MLD) should be recorded as they
correlate with the risk of radiation pneumonitis [15]. As target
volumes may be large, a V20 level of 35%–40% or an MLD of
20–23 Gy can be considered acceptable, but some patients
(10%–15%) may develop severe radiation-induced toxicity
[16]. Recent studies have explored an involved-field approach
without elective irradiation [17–19]. Furthermore, in
subgroup analysis of prospective trials, elderly patients with
good PS seem to have similar outcomes to younger patients
and age does not appear to impact on efficacy [20–22].
Toxicity, particularly haematological may be greater among
the elderly.
Recommendation 6: Limited-stage patients with good PS
should be considered for concomitant chemoradiotherapy,
taking into account the feasibility of radiation treatment plan
and good planning target volume coverage while maintaining
normal tissue dose constraints.
Strength of recommendation: A
Level of evidence: II
7. Other special metastatic situations
A single-centre five-arm randomised study indicated a 5.4% 5-
year improvement in a subgroup of patients with metastatic
disease who had either a complete or partial response within
the thorax and complete remission of distant disease after
initial chemotherapy with the use concomitant thoracic
radiotherapy and chemotherapy versus chemotherapy alone
[23]. The hypothesis generated by this subgroup analysis is
being addressed in a phase III multicentre study.
Recommendation 7: Thoracic radiotherapy given either
concomitantly or sequentially is currently not recommended in
patients with distant metastases that have responded to
chemotherapy.
Strength of recommendation: C
Level of evidence: II
8. Brain metastases as the only metastatic site
When the brain is the only documented metastatic site of
disease, the use of whole-brain radiotherapy and thoracic
radiotherapy in addition to chemotherapy may lead to more
favourable results, based on a small retrospective study of 30
patients [24]. Data from a prospective study are needed to
support the observation.
Recommendation 8: In patients with brain involvement as the
only metastatic site responding to chemotherapy, concomitant
chemotherapy with thoracic radiotherapy is currently not
recommended.
Strength of recommendation: C
Level of evidence: IV
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9. Which patients should be considered for
prophylactic cranial irradiation?
Prophylactic cranial irradiation (PCI) is recommended at the end
of initial therapy for patients with a tumour response and no
contraindications for this procedure. It is important to define
tumour response for consideration of PCI [25–27]. Although
chest X-ray was most often used in the older trials included in the
meta-analysis [25], the panel believes the restaging should be
done with the use of CT scan. The imaging should be carried out
at 3–4 weeks after the end of initial treatment, as at this stage the
determination of tumour response is not yet hampered by the
radiotherapy-induced fibrosis.
Recommendation 9: PCI is recommended for patients with
tumour response. Response should be determined by
a restaging CT scan.
Strength of recommendation: A
Level of evidence: I
10. Role of PCI in older patients
The mean age in the PCI meta-analysis was 59 with 25% of
patients being 65 years or older. However, age older than 60–65
is a risk factor for neurocognitive impairment [28, 29].
Recommendation 10: PCI in older patients, 65 years and
older, requires to balance the benefit and risk of possible
neurocognitive impairment to be considered.
Strength of recommendation: B
Level of evidence: II
FOLLOW-UP ISSUES
11. What is the optimal follow-up?
SCLC is likely to relapse or progress after initial treatment and
second-line treatment improves survival in good PS patients
[30]. Detecting a relapse or progression before deterioration of
PS is therefore a reasonable approach. Long-term survivors
may be at risk of second lung cancer that should be
histologically confirmed.
Recommendation 11: Subsequent follow-up should be at 2–3
months in non-progressing patients at the end of initial
treatment and response determination. The actual timing
depends on patient circumstances and availability of further
treatment. Imaging with CT is preferable.
Strength of recommendation: C
Level of evidence: V
TREATMENT ISSUES: SECOND-LINE
TREATMENT AND BEYOND
The majority of patients with SCLC experience relapse after their
initial treatment, with a median survival of 2–3 months without
second-line therapy. Although second-line therapy may
induce responses in 10%–40% of patients, these are usually
short-lived, and the median survival rarely exceeds 6 months
[31].
Three categories of disease have been described in the literature
regarding the response to initial therapy and the duration of
response: sensitive, resistant, and refractory. ‘Sensitive’ refers to
patients who have had a tumour response lasting 90 days or
longer. ‘Resistant’ refers to patients who have recurred within 90
days of completing therapy. ‘Refractory’ refers to patients with
tumours that never responded to first-line therapy or to those
who progressed during first-line therapy [30].
12. Sensitive disease
Patients having sensitive disease relapsing >90 days after first-
line treatment may benefit from retreatment.
Recommendation 12: Retreat with the same regimen that
induced their initial response, usually reinduction with
platinum/etoposide.
Strength of recommendation: C
Level of evidence: V
13. Resistant disease
In patients having resistant disease, topotecan improved overall
survival compared with best supportive care [31]. No statistically
significant difference in median survival was found in
a randomised trial comparing topotecan with combination
chemotherapy although topotecan caused less toxicity [32].
There is no evidence that combination chemotherapy is superior
to single-agent regimens. Both oral and i.v. topotecan had
similar efficacy but with slight differences in toxicity [33, 34].
Recommendation 13: Either oral or i.v. topotecan is
recommended for selected patients having resistant relapse, i.e.
not amenable to reinduction with first-line treatment.
Strength of recommendation: B
Level of evidence: II
14. Refractory disease and beyond second-line
treatment
A poor PS, early relapse (within 6 weeks) following first-line
treatment [30], and refractory disease are adverse prognostic
factors for response and for survival. There is currently no
standard second-line chemotherapy regimen for patients who
fail to respond to initial treatment (refractory disease) or who
relapse shortly after completion of first-line treatment (resistant
disease with early relapse) in contrast to resistant disease
having late relapse. Active agents from phase II trials include
amrubicin, topotecan, irinotecan, paclitaxel, docetaxel,
gemcitabine, ifosfamide, and oral etoposide (if etoposide not
included in first-line treatment). No drugs have so far been
approved by the Food and Drug Administration or the European
Medicines Agency for this indication.
Recommendation 14: Selected patients with good PS may
benefit from further treatment with a chemotherapy agent not
previously used.
Strength of recommendation: B
Level of evidence: III
15. Symptomatic local recurrence in mediastinum
Recommendation 15: Patients, not previously treated with
thoracic radiotherapy with a symptomatic recurrence in the
mediastinum, such as superior caval vein obstruction or
Annals of Oncology special article
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obstructed major airway, may benefit from thoracic
radiotherapy [35–37].
Strength of recommendation: C
Level of evidence: IV
16. Repeat cranial radiotherapy
For recurrence in the brain after PCI or whole-brain radiotherapy,
repeat radiotherapy may be useful in carefully selected patients if
no systemic treatment options are available [38–42].
Recommendation 16: Local brain re-irradiation, which may include
stereotactic radiotherapy, may be considered in selected patients.
Strength of recommendation: C
Level of evidence: V
FUTURE
Several trials could influence treatment options in the near
future. These include:
 The CONVERT and CALGB 30610 trials addressing the dose
and fractionation issues of concurrent thoracic
chemoradiotherapy in limited-stage SCLC.
 The ongoing individual data meta-analysis of early versus late
concurrent thoracic radiotherapy and chemotherapy.
 The CREST Dutch trial addressing the role of thoracic
radiotherapy in patients with restricted metastatic disease.
 Studies addressing the efficacy of novel systemic treatments,
including amrubicin and targeted agents.
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